Pharm 101: Gliclazide


Second generation sulphonylurea

Pharmacodynamics of sulphonylureas
  • Increase insulin release from pancreatic beta cells
    • Bind to receptor, cause inhibition of K efflux through a linked ATP-sensitive K channel, leads to extracellular depolarisation
    • This depolarisation opens a voltage-gated calcium channel, causing calcium influx and release of preformed insulin
  • Reduce serum glucagon levels with long term use
    • Unclear mechanism
    • May involve direct inhibition due to enhanced release of insulin and somatostatin which inhibit alpha-cell secretion
  • Other sulphonylureas:
    • 1st generation: tolbutamide, chlopropramide
    • 2nd generation: glipizide, glyburide
  • PO administration
  • Bioavailability 80%
  • Protein bound
  • Vd 20L
  • Hepatic metabolism to inactive or weakly active metabolites
  • Half-life 10 hours
  • Renal excretion (80%), remainder in bile
Clinical uses
  • Diabetes mellitus
Adverse effects
  • Hypoglycaemia (more common in elderly)
  • Weight gain
  • Flushing after alcohol ingestion
  • Dilutional hyponatraemia
  • Rarely, skin rashes or haematological toxicity (leukopaenia, thrombocytopaenia)
  • GI upset
  • CYP450 enzyme inducer
Further reading
Pharm 101 700

Pharmacology 101

Top 200 drugs

MBBS CCPU (RCE, Biliary, DVT, E-FAST, AAA) Rob is an Emergency Medicine Advanced Trainee based in Melbourne, Australia. He has special interests in medical education, ECG interpretation, and the use of diagnostic and procedural ultrasound in the undifferentiated and unwell patient.

Follow him on twitter: @rob_buttner | ECG Library |

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.